Emerging topical drugs for the treatment of rosacea
- 2 January 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Emerging Drugs
- Vol. 26 (1), 27-38
- https://doi.org/10.1080/14728214.2021.1887138
Abstract
Introduction: Rosacea is a common, chronic and relapsing inflammatory skin disease of the centrofacial area. Despite advancing knowledge on its pathogenesis, diagnosis, and treatment, some major unknowns still remain, including systematic evidence-based guidelines useful both for clinical assessment and therapeutic management. Topical treatment is regarded as a first-line option for mild to moderate rosacea and includes traditional and new FDA-approved prescription drugs, as well as off-label alternative topical agents. Areas covered: Since improved awareness of rosacea pathogenetic mechanisms has led to the development of new potential therapeutic agents, a search was performed on the ClinicalTrial.gov registry. The results identified several investigational topical drugs able to target one or more of the pathogenetic factors of rosacea. Expert opinion: The main unmet needs in the topical treatment of rosacea remain the management of vasomotor flushes and telangiectasias, as well as of troublesome symptoms such as burning and/or stinging. No single agent effective on all rosacea phenotypes is available so far, and preventive treatments capable of halting disease progression have not been identified yet. Finally, data on long-term efficacy and tolerability are still incomplete, especially for drugs more recently introduced in the market.Keywords
This publication has 72 references indexed in Scilit:
- Effects of a Facial Cream Containing the Minor Alkaloid Anatabine on Improving the Appearance of the Skin in Mild to Moderate Rosacea: An Open-Label Case Series StudyCase Reports in Dermatology, 2013
- Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gelJournal of the American Academy of Dermatology, 2013
- Neurovascular Aspects of Skin Neurogenic InflammationJournal of Investigative Dermatology Symposium Proceedings, 2011
- Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studiesBritish Journal of Dermatology, 2011
- Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing linkJournal of the European Academy of Dermatology and Venereology, 2011
- Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation modelsInternational Journal of Antimicrobial Agents, 2009
- Current topical and systemic approaches to treatment of rosaceaJournal of the European Academy of Dermatology and Venereology, 2009
- Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trialBritish Journal of Dermatology, 2008
- Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot studyClinical and Experimental Dermatology, 2005
- Topical MetronidazoleAmerican Journal of Clinical Dermatology, 2000